Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16039240.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Doxorubicin-induced cardiomyopathy is not uncommon and may progress to end-stage heart failure. Treatment of this condition with heart transplantation, however, requires that the primary malignancy be deemed "cured." We present the case of a 55- year-old woman who had doxorubicin-induced cardiomyopathy and non-Hodgkin's lymphoma. The active status of her lymphoma precluded heart transplantation. She had end-stage heart failure and underwent the insertion of a left ventricular assist device as a destination therapy.
Medical subject headings
- Antibiotics, Antineoplastic
- Cardiomyopathies
- Doxorubicin
- Heart Failure
- Heart-Assist Devices